SCHEMBL5049546

SCHEMBL5049546

CC[C@H](C)CC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276778 1.00
SCHEMBL13366391 1.00
Ethane SCHEMBL8514870 0.97 CA1 (0.36)
Hydrochloric Acid SCHEMBL10336374 0.97
SCHEMBL3392036 0.85 ALDH1A1 (0.38)
SCHEMBL19619339 0.80 CA1 (0.37)
SCHEMBL11413659 0.80 ECE1 (0.35)
Acetamide SCHEMBL4103797 0.80 LMNA (0.47)
SCHEMBL25078569 0.79
SCHEMBL276380 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338588-A1 Granzyme B Directed Imaging and Therapy THE GENERAL HOSPITAL CORPORATION 2023-10-26 US disclosed
US-20230312650-A1 Antifungal Peptides, Compounds Including The Same, And Methods Of Use Thereof SETON HALL UNIVERSITY (US) 2023-10-05 US disclosed
CN-111454436-B Preparation method of chiral conjugated microporous polymer containing (S) -N-sec-butylacetamide 齐齐哈尔大学 2022-12-20 CN disclosed
US-20170290878-A1 METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES ENDOCYTE INC (US) 2017-10-12 US disclosed
WO-2017175233-A1 PROCESS FOR LARGE SCALE LIQUID PHASE SYNTHESIS OF CARBETOCIN AND ITS NOVEL INTERMEDIATES DAVULURI RAMAMOHAN RAO (IN) 2017-10-12 WO disclosed
US-20120041019-A1 PROTEASE INHIBITORS AMPLYX PHARMACEUTICALS, INC. 2012-02-16 US disclosed
WO-2010053546-A2 CRF1 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
WO-2010053545-A2 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed
US-7375127-B2 Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) AE ZENTARIS GMBH (DE) 2008-05-20 US disclosed
US-20060014818-A1 Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs) MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2006-01-19 US disclosed
EP-0954526-A2 SERINE PROTEASE INHIBITORS CORTECH, INC. (US) 1999-11-10 EP disclosed
WO-1998024806-A2 SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE SERINE PROTEASE INHIBITORS CORTECH, INC. (US) 1998-06-11 WO disclosed